Streetbeat News

Stock Prices

TJX

TJX Companies reported Q2 2025 earnings per share of $0.96, surpassing the analyst estimate of $0.91. The company's sales reached $13.468 billion, exceeding the expected $13.307 billion and marking a 5.57% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:33 am

VGR

Vector Group shares rise following the announcement of a definitive agreement to be acquired by JT Group.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:29 am

ARKB

ETHA

ETHE

ETHW

GBTC

IBIT

Bitcoin and Ethereum ETFs show mixed flows with Bitcoin ETFs seeing significant inflows, while Ethereum ETFs experience outflows. Despite this, both cryptocurrencies are down. Tron stands out with a 12.5% gain due to developments in its ecosystem. Solana's ETF prospects in the US remain uncertain.

Portfolio Pulse from Murtuza Merchant

August 21, 2024 | 11:27 am

NITO

SRL

TANH

The article highlights three oversold stocks in the materials sector with potential for short-term gains: Tantech Holdings Ltd (TANH), N2OFF Inc (NITO), and Scully Royalty Ltd (SRL). These stocks have low RSI values, indicating they may be undervalued.

Portfolio Pulse from Avi Kapoor

August 21, 2024 | 11:26 am

GDS

GDS Holdings reported a Q2 loss of $(0.18) per share, beating the expected $(0.26) loss. However, sales of $388.92M slightly missed the $389.37M estimate. Sales increased by 14.08% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:07 am

GDS

GDS Holdings shares are experiencing an upward trend following the release of their Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:06 am

GDS

GDS Holdings reported Q2 earnings per ADS of $(0.18) and sales of $388.92 million, missing the analyst consensus estimate by 86.06%. Despite this, sales increased by 14.08% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:04 am

ADI

Analog Devices shares rise due to strong Q3 financial results, surpassing expectations.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:03 am

BPTH

Bio-Path Holdings announced an update from its Phase 1/1b trial of BP1001-A in solid tumor patients. The first patient treated with a higher dose experienced tumor reduction and stable disease.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:03 am

OKYO

OKYO Pharma's Executive Chairman, Gabriele Cerrone, through Panetta Partners Limited, purchased 35,000 shares of OKYO Pharma on Nasdaq at $1.00 per share.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:01 am